CCM
VRTX icon

Copernicus Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Copernicus Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-9,000
Closed -$1.81M – 17
2021
Q2 		$1.81M Buy
9,000
+6,000
+200% +$1.26M 28.62% 1
2021
Q1 		$645K Sell
3,000
-85
-3% -$18.7K 10.42% 5
2020
Q4 		$729K Sell
3,085
-41,904
-93% -$9.61M 11.36% 2
2020
Q3 		$12.2M Buy
44,989
+22,684
+102% +$6.26M 11.66% 4
2020
Q2 		$6.47M Sell
22,305
-30,148
-57% -$8.17M 7.1% 5
2020
Q1 		$12.5M Sell
52,453
-5,362
-9% -$1.23M 15.1% 1
2019
Q4 		$12.7M Sell
57,815
-7,034
-11% -$1.42M 16.6% 1
2019
Q3 		$11M Sell
64,849
-6,000
-8% -$1.06M 10.22% 2
2019
Q2 		$13M Buy
70,849
+52,986
+297% +$9.26M 11.56% 1
2019
Q1 		$3.29M Sell
17,863
-15,020
-46% -$2.77M 8.43% 5
2018
Q4 		$5.45M Sell
32,883
-30,024
-48% -$5.2M 10.26% 4
2018
Q3 		$12.1M Sell
62,907
-3,533
-5% -$629K 11.39% 4
2018
Q2 		$11.3M Buy
66,440
+14,196
+27% +$2.2M 8.2% 5
2018
Q1 		$8.52M Sell
52,244
-10,047
-16% -$1.64M 6.79% 7
2017
Q4 		$9.34M Buy
+62,291
New +$9.22M 6.95% 5

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Copernicus Capital Management's VRTX Position: Q3 2021 in Review

Copernicus Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2021, closing a stake of 9,000 shares — an estimated $1.81M sold.

Copernicus Capital Management first reported a position in VRTX in Q4 2017 and held it in 15 quarters. The position peaked at $13M in Q2 2019. 933 funds tracked by Wall St. Rank hold VRTX as of Q3 2021.

  • Copernicus Capital Management reported no remaining Vertex Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Copernicus Capital Management sold 9,000 Vertex Pharmaceuticals shares in Q3 2021, an estimated $1.81M.
  • Copernicus Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2017 and held it in 15 quarters.
  • Copernicus Capital Management's Vertex Pharmaceuticals position peaked at $13M in Q2 2019.
  • 933 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2021.

Based on Copernicus Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.